SHIM
CTKB icon

Stone House Investment Management’s Cytek Biosciences CTKB Stock Holding History

Stone House Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-318
Closed -$1.39K – 1368
2026
Q1 		$1.39K Buy
+318
New +$1.5K ﹤0.01% 653

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stone House Investment Management's CTKB Position: Q2 2026 in Review

Stone House Investment Management sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 318 shares — an estimated $1.39K sold.

Stone House Investment Management first reported a position in CTKB in Q1 2026 and held it in 1 quarter. The position peaked at $1.39K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Stone House Investment Management reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Stone House Investment Management sold 318 Cytek Biosciences shares in Q2 2026, an estimated $1.39K.
  • Stone House Investment Management first reported a position in Cytek Biosciences in Q1 2026 and held it in 1 quarter.
  • Stone House Investment Management's Cytek Biosciences position peaked at $1.39K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.